{"id":"placebo-for-levosimendan","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Headache"},{"rate":"10-20%","effect":"Nausea"},{"rate":"5-10%","effect":"Dizziness"},{"rate":"5-10%","effect":"Flushing"}]},"_chembl":{"chemblId":"CHEMBL2051955","moleculeType":"Small molecule","molecularWeight":"280.29"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Levosimendan works by binding to troponin C and increasing the sensitivity of cardiac myofilaments to calcium, leading to increased cardiac contractility without increasing oxygen demand. This results in improved cardiac function without increasing the risk of arrhythmias or other adverse effects associated with traditional inotropes.","oneSentence":"Levosimendan is a calcium sensitizer that increases cardiac contractility without increasing oxygen demand.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:27:08.691Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute heart failure"},{"name":"Severe heart failure"}]},"trialDetails":[{"nctId":"NCT04158674","phase":"PHASE3","title":"Interest of Levosimendan in Reducing Weaning Failures of ExtraCorporeal Life Support - ECLS","status":"TERMINATED","sponsor":"Centre Hospitalier Universitaire Dijon","startDate":"2020-02-24","conditions":"Acute Decompensated Heart Failure","enrollment":82},{"nctId":"NCT07105202","phase":"PHASE4","title":"Shorter Weaning From Invasive Ventilation With Levosimendan","status":"RECRUITING","sponsor":"Radboud University Medical Center","startDate":"2025-09-17","conditions":"Mechanical Ventilation, Weaning Failure","enrollment":250},{"nctId":"NCT05664191","phase":"PHASE2","title":"Levosimendan as Treatment of Aneurysmal SubArachnoid Haemorrhage","status":"RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2023-10-13","conditions":"Sub-arachnoid Haemorrhage","enrollment":30},{"nctId":"NCT04020263","phase":"PHASE3","title":"Effect of Early Use of Levosimendan Versus Placebo on Top of a Conventional Strategy of Inotrope Use on a Combined Morbidity-mortality Endpoint in Patients With Cardiogenic Shock","status":"RECRUITING","sponsor":"Pr Bruno LEVY","startDate":"2023-07-03","conditions":"Cardiogenic Shock","enrollment":610},{"nctId":"NCT04705337","phase":"PHASE4","title":"Levosimendan In Ambulatory Heart Failure Patients","status":"TERMINATED","sponsor":"Medical University of Bialystok","startDate":"2021-12-15","conditions":"Heart Failure New York Heart Association Class III, Heart Failure New York Heart Association Class IV, Heart Failure, Systolic","enrollment":70},{"nctId":"NCT04329624","phase":"PHASE3","title":"Effect Levosimendan Administration on Postoperative NT-proBNP in Cardiac Risk Patients","status":"COMPLETED","sponsor":"Medical University of Vienna","startDate":"2020-10-10","conditions":"Cardiovascular Risk Factor","enrollment":230},{"nctId":"NCT03541603","phase":"PHASE2","title":"Hemodynamic Evaluation of Levosimendan in Patients With PH-HFpEF","status":"COMPLETED","sponsor":"Tenax Therapeutics, Inc.","startDate":"2018-11-14","conditions":"Hypertension Pulmonary Secondary, Heart Failure, Right Sided, Heart Failure With Normal Ejection Fraction","enrollment":44},{"nctId":"NCT05956431","phase":"PHASE4","title":"RCT Study of Levosimendan Improving Prognosis of Cardiac Arrest","status":"UNKNOWN","sponsor":"Peking University Third Hospital","startDate":"2023-08-01","conditions":"Heart Arrest","enrollment":60},{"nctId":"NCT03022877","phase":"NA","title":"Acute and Chronic Protective Effects of Peri-interventional Administration of Levosimendan in ST Elevation Myocardial Infarctions","status":"WITHDRAWN","sponsor":"RWTH Aachen University","startDate":"2017-06","conditions":"Myocardial Infarction, Outcome","enrollment":""},{"nctId":"NCT03505021","phase":"PHASE3","title":"Effects of Oral Levosimendan (ODM-109) on Respiratory Function in Patients With ALS","status":"COMPLETED","sponsor":"Orion Corporation, Orion Pharma","startDate":"2018-06-21","conditions":"Amyotrophic Lateral Sclerosis","enrollment":496},{"nctId":"NCT04970238","phase":"PHASE4","title":"Effect of Levosimendan on Left Ventricular Systolic Function and Heart Failure After PCI in Patients With Acute Anterior Myocardial Infarction","status":"UNKNOWN","sponsor":"Zhijun Sun","startDate":"2021-10","conditions":"ST Elevation Myocardial Infarction, Heart Failure","enrollment":500},{"nctId":"NCT02531724","phase":"PHASE4","title":"Effects of Levosimendan in Acute Kidney Injury After Cardiac Surgery","status":"COMPLETED","sponsor":"Sahlgrenska University Hospital","startDate":"2015-09","conditions":"Acute Kidney Injury, Renal Insufficiency, Acute","enrollment":30},{"nctId":"NCT03699215","phase":"PHASE3","title":"Clinical Trial in Patients Who Have Suffered a Heart Attack and Who Have Undergone Catheterization Treated With Levosimendan","status":"UNKNOWN","sponsor":"Hospital Universitario de Canarias","startDate":"2018-11-17","conditions":"ST Elevation Myocardial Infarction","enrollment":184},{"nctId":"NCT04573049","phase":"PHASE4","title":"The Effectiveness and Safety of Levosimendan in Patients With Severe Aortic Stenosis and Heart Failure Undergoing Transcatheter Aortic Valve Replacement","status":"UNKNOWN","sponsor":"China National Center for Cardiovascular Diseases","startDate":"2020-09-01","conditions":"Aortic Valve Stenosis, Heart Failure, Inotropic Agents","enrollment":124},{"nctId":"NCT04179604","phase":"PHASE2, PHASE3","title":"Spanish Randomized Clinical Trial to Compare Levosimendan Versus Placebo in Postoperative Cardiac Surgery (SPARTANS)","status":"UNKNOWN","sponsor":"María de los Ángeles Tena Pajuelo","startDate":"2020-06-17","conditions":"Cardiac Output, Low","enrollment":300},{"nctId":"NCT01500785","phase":"PHASE4","title":"Intracoronary Administration of Levosimendan in Cardiac Surgery Patients","status":"TERMINATED","sponsor":"Tampere University Hospital","startDate":"2018-06-15","conditions":"Myocardial Stunning","enrollment":50},{"nctId":"NCT03576677","phase":"PHASE4","title":"Effect of Levosimendan or Placebo on Exercise in Advanced Chronic Heart Failure","status":"UNKNOWN","sponsor":"Finn Gustafsson","startDate":"2019-08-01","conditions":"Heart Failure","enrollment":42},{"nctId":"NCT01188369","phase":"PHASE4","title":"Effects of Levosimendan in Patients Eligible for Aortic Valve Replacement With Left Ventricular Hypertrophy","status":"TERMINATED","sponsor":"University of Aarhus","startDate":"2010-09","conditions":"Diastolic Dysfunction, Left Ventricular Hypertrophy","enrollment":20},{"nctId":"NCT03437226","phase":"PHASE3","title":"Repetitive Levosimendan Infusion for Patients With Advanced Chronic Heart Failure","status":"UNKNOWN","sponsor":"Dr. Gerhard Pölzl","startDate":"2018-03-08","conditions":"Heart Failure","enrollment":264},{"nctId":"NCT02025621","phase":"PHASE3","title":"Levosimendan in Patients With Left Ventricular Systolic Dysfunction Undergoing Cardiac Surgery On Cardiopulmonary Bypass","status":"COMPLETED","sponsor":"Tenax Therapeutics, Inc.","startDate":"2014-07","conditions":"Coronary Artery Bypass Grafting, Mitral Valve Surgery, Low Cardiac Output Syndrome","enrollment":882},{"nctId":"NCT02487407","phase":"PHASE2","title":"Effects of ODM-109 on Respiratory Function in Patients With Amyotrophic Lateral Sclerosis","status":"COMPLETED","sponsor":"Orion Corporation, Orion Pharma","startDate":"2015-07","conditions":"Amyotrophic Lateral Sclerosis","enrollment":66},{"nctId":"NCT01720030","phase":"PHASE2, PHASE3","title":"Levosimendan in Acute Kidney Injury Study","status":"UNKNOWN","sponsor":"VieCuri Medical Centre","startDate":"2016-09","conditions":"Acute Kidney Injury","enrollment":68},{"nctId":"NCT01536132","phase":"PHASE4","title":"Intermittent Intravenous Levosimendan in Ambulatory Advanced Chronic Heart Failure Patients","status":"COMPLETED","sponsor":"Parc de Salut Mar","startDate":"2010-04","conditions":"Heart Failure","enrollment":70},{"nctId":"NCT02261948","phase":"PHASE4","title":"Levosimendan Efficacy Assessment by Cardiopulmonary Exercise Test (CPET)","status":"COMPLETED","sponsor":"Centro Cardiologico Monzino","startDate":"2012-09","conditions":"Heart Failure","enrollment":42},{"nctId":"NCT01721434","phase":"PHASE2, PHASE3","title":"Effects of Levosimendan on Diaphragm Function in Mechanically Ventilated Patients","status":"UNKNOWN","sponsor":"University Medical Center Nijmegen","startDate":"2012-09","conditions":"Muscle Weakness Conditions, Weaning Failure","enrollment":42},{"nctId":"NCT01595737","phase":"PHASE4","title":"Comparison of the Administration of Levosimendan and Placebo in the Preparation of Critical Patients for Heart Surgery","status":"COMPLETED","sponsor":"Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau","startDate":"2011-02","conditions":"Cardiac Surgery","enrollment":30},{"nctId":"NCT00988806","phase":"PHASE4","title":"Long-Term Intermittent Administration of Levosimendan in Patients With Advanced Heart Failure","status":"UNKNOWN","sponsor":"Hospital Universitario de Canarias","startDate":"2009-11","conditions":"Advanced Heart Failure","enrollment":213},{"nctId":"NCT01221116","phase":"NA","title":"Inotropic Treatment With Levosimendan (SimdaxR)in Heart Surgery","status":"TERMINATED","sponsor":"Ullevaal University Hospital","startDate":"2003-01","conditions":"Heart Failure, Cardiac Surgery","enrollment":23},{"nctId":"NCT01065194","phase":"PHASE3","title":"Efficacy and Safety of Pulsed Infusions of Levosimendan in Outpatients With Advanced Heart Failure","status":"UNKNOWN","sponsor":"Medical University Innsbruck","startDate":"2009-08","conditions":"Chronic Stable Heart Failure","enrollment":120}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":240,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Placebo for ODM-109"],"phase":"phase_3","status":"active","brandName":"Placebo for levosimendan","genericName":"Placebo for levosimendan","companyName":"Orion Corporation, Orion Pharma","companyId":"orion-corporation-orion-pharma","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Levosimendan is a calcium sensitizer that increases cardiac contractility without increasing oxygen demand. Used for Acute heart failure, Severe heart failure.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}